# Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

> **NCT04003246** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Lung Cancer Stage III

## Interventions

- **RADIATION:** Thoracic RT and Durvalumab
- **DRUG:** Consolidative Durvalumab

## Key facts

- **NCT ID:** NCT04003246
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-03
- **Primary completion:** 2022-06-15
- **Final completion:** 2024-11-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003246, "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04003246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*